Blueberry Therapeutics have unique nanopolymer drug delivery technology... ...which opens up huge opportunities to rapidly develop new medicines... ...and helps us find ways to treat dermatological disorders.
Today, Blueberry Therapeutics published our latest peer-reviewed scientific paper. The paper entitled “Assessment of the nail penetration of antifungal agents, [...]
Susan Yau2020-03-03T10:03:51+00:00February 27th, 2020|
A Blueberry case study
In this video, CEO John Ridden and CSO David Cook talk about the early days of Blueberry Therapeutics, the short term and long term plans for the company, and the benefits of being based at Alderley Park, Cheshire.